Cancer Crosslinks 2024
Registration is now open – click here
Bridging innovations to improve clinical outcomes for cancer patients.
You are invited to join distinguished speakers from Germany, France, UK & USA as they address emerging diagnostic and treatment options for solid and hematological cancers. This meeting promotes interaction between researchers and clinicians to enhance translational and clinical research and encourage new collaborations.
The event will be held on-site at Oslo Cancer Cluster Innovation Park with a digital option.
Daytime Educational Program: 10:30 – 16:15 (Registrations begin at 10:00)
Afternoon Networking Program: 16:15 onwards.
| Cancer Crosslinks 2024 – PROGRAM | |
|
From 10:00 |
Registration on-site & Log-in for live-stream |
|
10:30 – 10:45 |
Opening and welcome, Oslo Cancer Cluster |
|
10:45 – 10:50 Moderators |
SESSION 1 – EXPLORING THE FUTURE OF CANCER IMMUNOTHERAPY Marte Grønlie Cameron, Clinical Oncologist, Palliative Care Unit and Head of Research at the Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway. |
|
10:50 – 11:35 |
Opening keynote address Sonja Loges,Professor, Director, DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Dept of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim,University of Heidelberg, Mannheim; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), German Center for Lung Research (DZL), Heidelberg, Germany |
|
11:35 – 12:15 |
Microbiota-centered interventions and cancer immunotherapy: recent learnings and clinical implications Lisa Derosa, Immuno-Oncologist, Associate Professor, Clinical Director of Clinicobiome, The Microbiome Clinic, U1015 Tumour Immunology and Anti-Cancer Immunotherapy Unit, Zitvogel Lab, Institut Gustave Roussy, Paris, France. |
|
12:15 – 13:00 |
Lunch Break |
|
13:00 – 13:05 Moderators |
SESSION 2 – IMPACTS ON CLINICAL OUTCOMES BY TARGETING TUMOR HETEROGENEITY Fredrik Schjesvold, Leader of Oslo Myeloma Center, Dept. of Haematology, Oslo University Hospital, Norway. Head of the Norwegian Myeloma Association, President of the Nordic Myeloma Study Group and board member of the European Myeloma Network. Katrin Kleinmanns, Researcher, Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway. |
|
13:05 – 13:45 |
Tumor heterogeneity in multiple myeloma: clinical consequences? Leo Rasche, Senior physician, Specialist in Internal Medicine, Haematology and Oncology, University Hospital Würzburg, Junior Group Leader, Mildred Scheel Nachwuchszentrum (MSNZ) for Cancer Research, Germany. |
|
13:45 – 14:20 |
Highly multiplexed imaging for precision breast immuno-oncology Raza Ali, Group Leader, Systems Cancer Pathology Lab, Honorary Consultant Pathologist, Cancer Research UK Cambridge Institute, University of Cambridge, UK. |
|
14:20 – 14:50 |
Coffee break |
|
14:50 – 14:55 Moderators |
SESSION 3 – EMERGING PLATFORMS FOR CANCER TREATMENT DELIVERY Marte Grønlie Cameron, Clinical Oncologist, Palliative Care Unit and Head of Research at the Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway. |
|
14:55 – 15:35 |
Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer. Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
|
15:35 – 16:05 |
Revolutionizing Oncology: AI-Driven Innovations on Cancer Pathways Mihaela van der Schaar, John Humphrey Plummer Professor of Machine Learning, AI, and Medicine. Director, Cambridge Center for AI in Medicine, University of Cambridge, UK. |
|
16:05 – 16:15 |
Closing remarks |
|
From 16:15 |
An invitation to join the afternoon networking event. |
The Invitation & Program may be downloaded HERE.
For more information about Cancer Crosslinks and/or to contact the organizing team, please visit the website: cancercrosslinks.com
Organizer: Sponsors:
TRAVEL VOUCHER: A limited number of travel vouchers (within Norway) are available for clinicians and healthcare personnel (first come, first served). To inquire, please contact Charlotte Homme, Head of Membership & Events, cwh@oslocancercluster.no
